HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers
批准号:
10686743
负责人:
Donald Lo
金额:
$85.3万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
1-Phosphatidylinositol 3-KinaseAddressApoptosisBiological AssayCancer cell lineCell CycleCell Cycle ArrestCell LineCell ProliferationCellsCollaborationsCyclin D1DevelopmentDigit structureDoseDrug KineticsEhrlich Tumor CarcinomaEmployeeEpidermal Growth FactorEpidermal Growth Factor ReceptorFLT3 geneFormulationHDAC4 geneHDAC6 geneHistone DeacetylaseHistone Deacetylase InhibitorHumanInternationalJointsJournalsLeadLegal patentLinkLiteratureMalignant NeoplasmsMethodsModelingMusNational Center for Advancing Translational SciencesNecrosisPathway interactionsPatientsPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPhosphatidylinositolsPhosphotransferasesPolymersPublicationsPublishingReceptor Protein-Tyrosine KinasesReportingResistanceResistance developmentSignal TransductionTechnologyTestingTherapeuticToxic effectTranslatingTumor Suppressor ProteinsTyrosine Kinase InhibitorUp-RegulationWorkangiogenesisbasec-myc Genescancer initiationcancer therapycell killingdesignimprovedin vivoinhibitorinventionkinase inhibitorlead optimizationmalignant breast neoplasmmutantnanonanoencapsulatednanomolarnanoparticlenovelrare cancersynergismtumortumor growthuptake
中文摘要
之前,我们设计并合成了新型双重HDAC/PI 3 K抑制剂,鉴定了几种新型分子,其以个位数纳摩尔效力抑制两种靶标。已在NCI 60细胞系组中测试了选定的化合物,在几种细胞系中显示出抗增殖和细胞杀伤活性。在基于细胞的靶标接合测定中检查了其中的一个子集,证实了双重抑制剂在细胞中接合PI 3 K-δ和HDAC 6。先导化合物(TRND 00507679)在几种突变型和FLT 3耐药AML细胞系和AML患者的原代母细胞中诱导坏死。我们已经开发了TRND 00507679和TRND 00421925的纳米颗粒制剂,并研究了它们在几种人类癌细胞系中的细胞摄取和抗增殖活性。TRND 00507679包封的纳米颗粒(TRND 00507679-NP)在体内乳腺癌埃利希腹水肿瘤(EAT)模型中显示出对肿瘤生长的剂量依赖性抑制。此外,我们还比较了由PI 3 K-δ抑制剂、基于Idelalisib的纳米颗粒(Idelalisib-NP)与TRND 00507679-NP引起的肿瘤生长抑制。 与Idelalisib-NP相反,小鼠中EAT肿瘤的治疗与TRND 00507679-NP显著降低肿瘤生长相关。所描述的工作发表在Journal of Medicinal Chemistry上。
目前的努力已经导致了一项国际专利的出版,该专利的名称为:用于治疗癌症的磷酸肌醇3-激酶和组蛋白脱乙酰酶的抑制剂。此外,Hillstream Bioburma,Inc.这些纳米配制的PI 3 K-δ/HDAC 6双重抑制剂的NCATS是通过最近提交的题为“包含组蛋白脱乙酰酶6/磷酸肌醇3-激酶-δ双重抑制剂的聚合物纳米颗粒和相关方法”的雇员发明记录(EIR)发起的。
英文摘要
Previously we designed and synthesized novel dual HDAC/PI3K inhibitors, identifying several novel molecules that inhibit both targets with single digit nanomolar potency. Selected compounds have been tested in the NCI60 cell line panel, showing anti-proliferation and cell-killing activity in several cell lines. A subset of these were examined in cell-based target engagement assays, confirming that the dual inhibitors engage both PI3K-delta and HDAC6 in cells. The lead compound (TRND00507679) induced necrosis in several mutant and FLT3-resistant AML cell lines and primary blasts from AML patients. We have developed the nano-particle formulation for TRND00507679 and TRND00421925 and studied their cellular uptake and anti-proliferative activity in several human cancer cell lines. TRND00507679 encapsulated nano-particles (TRND00507679-NPs) displayed a dose-dependent inhibition of tumor growth in an in vivo breast cancer Ehrlich ascites tumor (EAT) model. Additionally, we have also compared the tumor growth inhibition caused by PI3K-delta inhibitor, Idelalisib based nano-particles (Idelalisib-NPs) with that of TRND00507679-NPs. In contrast to Idelalisib-NPs, treatment of EAT tumors in mice was associated with substantial reduction in tumor growth by TRND00507679-NPs. The described work was published in the Journal of Medicinal Chemistry.
Current efforts have resulted in the publication of an international patent titled: Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer. Additionally, filing of a joint inventorship patent between Hillstream Biopharma, Inc. and NCATS for these nano-formulated PI3K-delta/HDAC6 dual inhibitors was launched by recent submission of an Employee Invention Record (EIR) titled: Polymeric nanoparticles comprising a histone deacetylase 6/phosphoinositide 3-Kinase-delta dual inhibitor and related methods.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer
-
批准号:10470633
-
项目类别:
-
资助金额:$110.47万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer
-
批准号:10685882
-
项目类别:
-
资助金额:$154.65万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers
-
批准号:10470638
-
项目类别:
-
资助金额:$107.1万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Evaluation of ACT1 to Treat Diabetic Keratopathy
-
批准号:10470634
-
项目类别:
-
资助金额:$121.52万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Helping to End Addiction Long-term (HEAL): Development of Clinical Candidate Drugs for Pain, Addiction and Overdose
-
批准号:10686744
-
项目类别:
-
资助金额:$1031.68万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2
-
批准号:10686748
-
项目类别:
-
资助金额:$77.54万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
HDAC/PI3K Dual Inhibitors for Treatment of Rare Cancers
-
批准号:10259368
-
项目类别:
-
资助金额:$50.28万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2
-
批准号:10259371
-
项目类别:
-
资助金额:$199.15万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
HEAL: Development of Clinical Candidate Drugs for Pain, Addiction and Overdose
-
批准号:10259369
-
项目类别:
-
资助金额:$1029.92万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Gene Therapy Platform for Rare Diseases
-
批准号:10259364
-
项目类别:
-
资助金额:$516.43万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Development of Nogo Receptor Decoy for the Treatment of Spinal Cord Injury
-
批准号:10686732
-
项目类别:
-
资助金额:$580.05万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
COVID-19: Identification and Development of Clinical Candidates to Treat SARS-CoV-2
-
批准号:10510410
-
项目类别:
-
资助金额:$364.33万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
IND-Enabling Pre-Clinical Studies of 2DG for Treatment of Epilepsy
-
批准号:10686733
-
项目类别:
-
资助金额:$130.62万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Gene Therapy Platform for Rare Diseases
-
批准号:10687752
-
项目类别:
-
资助金额:$624.65万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Short Stabilized EPO-Peptide as Therapeutic Agents for Multiple Sclerosis and Acute Brain Trauma
-
批准号:10685883
-
项目类别:
-
资助金额:$130.62万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Antisense Oligonucleotide (ASO) Development for Rare and Neglected Diseases
-
批准号:10686747
-
项目类别:
-
资助金额:$145.0万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Evaluation of ACT1 to Treat Diabetic Keratopathy
-
批准号:10686731
-
项目类别:
-
资助金额:$130.62万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Development of Drinabant for Treatment of Acute Cannabinoid Overdose
-
批准号:10686746
-
项目类别:
-
资助金额:$120.03万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
BPN14770 For Treatment of Fragile X Syndrome
-
批准号:10011440
-
项目类别:
-
资助金额:$58.5万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer
-
批准号:10261232
-
项目类别:
-
资助金额:$34.02万
-
财政年份:--
-
负责人:Donald Lo
-
依托单位:
海外基金